2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1127

Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1559

Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1586

Resistant Hypertension Is Associated with Inflammation, Renal Function, and Increased Mortality in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

9:00AM-11:00AM: Abstract Number: 1184

Response to Methotrexate and Glucocorticoid Injection in New Onset Arthritis after Checkpoint Inhibitor Therapy

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1082

Responsiveness and Minimally Clinically Important Differences of Promis Measures in Rheumatoid Arthritis

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1264

Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests (CATs) in Systemic Lupus Erythematosus (SLE)

Patient Outcomes, Preferences, and Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1330

Rhesus Theta Defensin 1 (RTD-1) Suppresses Disease-Associated Genes and Induces Anti-Inflammatory Expression Signature in Synovial Tissues of Rat Model of Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models Poster II

9:00AM-11:00AM: Abstract Number: 1173

Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1156

Rheumatic Immune Related Adverse Events from Checkpoint Inhibitor Therapy for Cancer: Long-Term Follow up Data

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1153

Rheumatic Manifestations of Whim Syndrome

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1083

Rheumatoid Arthritis Patients Achieved Better Quality of Life Than Systemic Lupus Erythematosus Patients at Sustained Remission: The Impact of Disease Diagnosis on Health-Related Quality of Life Outcomes

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1087

Rheumatology Clinic Smoking Cessation Protocol Markedly Increases Quit Line Referrals

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1279

Risk Factors for Achieving a Drug-Free Remission in Patients with Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

9:00AM-11:00AM: Abstract Number: 1268

Risk Factors for Bone Loss in Juvenile-Onset Systemic Lupus Erythematosus: A Prospective Study

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

9:00AM-11:00AM: Abstract Number: 1618

Risk Factors for Development of Early Infectious and Non-Infectious Complications in Systemic Lupus Erythematosus Patients Undergoing Major Surgery

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].